Matthew Kelsey
Stock Analyst at HC Wainwright & Co.
(0.22)
# 4,360
Out of 5,049 analysts
7
Total ratings
25%
Success rate
-16.27%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Kelsey
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SNSE Sensei Biotherapeutics | Assumes: Buy | $100 | $8.68 | +1,052.07% | 1 | Jun 2, 2025 | |
| ACXP Acurx Pharmaceuticals | Assumes: Buy | $160 | $4.82 | +3,219.50% | 1 | May 15, 2025 | |
| DBVT DBV Technologies | Maintains: Equal-Weight | $260 → $100 | $14.36 | +596.38% | 5 | Dec 20, 2018 |
Sensei Biotherapeutics
Jun 2, 2025
Assumes: Buy
Price Target: $100
Current: $8.68
Upside: +1,052.07%
Acurx Pharmaceuticals
May 15, 2025
Assumes: Buy
Price Target: $160
Current: $4.82
Upside: +3,219.50%
DBV Technologies
Dec 20, 2018
Maintains: Equal-Weight
Price Target: $260 → $100
Current: $14.36
Upside: +596.38%